UroGen Pharma Ltd. (URGN) Q3 2026 earnings review
UroGen's bladder drug scales fast, but its older medicine shrinks
UroGen Pharma, a maker of non-surgical gels for urinary tract cancers, is growing fast on its newer bladder drug while its older treatment shrinks. Zusduri sales climbed 35% from last quarter to $68 million as chief executive Liz Barrett reported 662 prescribing doctors, lifting total revenue to $89 million and generating an $8 million operating profit. However, Jelmyto sales dropped, forcing the company to cut that drug's full-year outlook.
| Zusduri bladder drug sales | $68.0M +35% from last quarter |
|---|---|
| Jelmyto upper-tract drug sales | $21.0M −18% from a year ago (−12% excluding one-offs) |
| Operating profit | $8.3M $27.4M operating loss a year ago |
| Full-year Jelmyto sales outlook | Cut $9M to ~$90M from $97–101M |
⚖️ Verdict: 🟢 Bullish
The story got better because Zusduri added 210 prescribing doctors — more than in the second quarter — proving demand did not stall after Medicare activated its permanent billing code earlier this year. One caution: the long-expected cut to the Jelmyto plan arrived as rival clinical trials pulled patients away, and cash still fell by $17 million to $91 million.
The question now is whether rising operating profits will stop the cash drain before UroGen needs more borrowing. Either working-capital needs settle down so the 92% gross margin builds cash within two quarters, or inventory and interest bills force UroGen to draw its extra $50 million loan tranche. Fourth-quarter cash and Zusduri additions will settle it.
🐂 Bull Case
Zusduri Prescriber Additions Sped Up
Zusduri, UroGen's non-surgical gel for recurring bladder cancer, is the engine of the business. Chief executive Liz Barrett said "growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity" after cautioning last quarter that growth would be steady rather than faster.
Doctors adopted the drug at a faster clip in the third quarter even as revenue per doctor dipped slightly. The cancer drug maker added 210 new prescribing doctors, up from 196 additions in the second quarter, while quarterly revenue grew $17.6 million from last quarter.
- Zusduri revenue: $68.0 million, up 34.9% from last quarter
- Unique prescribing doctors: 662, up from 452 in the second quarter
- Repeat prescribing doctors: 331, or 50% of the total, up from 45% last quarter
- Activated treatment clinics: 1,538, up by 94 sites from June
- Revenue per prescribing doctor: $103,000 by our math, down from $112,000 last quarter
This matters because the first-quarter jump after Medicare assigned a permanent billing code was not a one-time bump. Adding $17.6 million in quarterly sales keeps the launch ahead of the roughly $14 million per quarter pace needed to reach management's $1 billion peak sales goal.
What to watch: fourth-quarter unique prescriber additions and revenue per doctor. Another quarter of 200 new doctors with steady revenue per doctor would show that community clinics are converting enrolled patients into routine treatments.
Sales Growth Lifted Operating Profit to $8.3 Million
Because UroGen keeps more than 91 cents of gross profit on every dollar of drug sales, rising Zusduri revenue quickly covers its overhead costs. After barely breaking even in the second quarter with $0.1 million of operating profit, the biotechnology group generated $8.3 million in operating profit, or 9.4% of revenue.
By our math, selling and administrative costs — sales reps, marketing and overhead — dropped by 83.7 percentage points of revenue from a year ago to 53.0%, while research and development — clinical trial and regulatory costs — fell 21.8 percentage points to 29.2%. What to watch: fourth-quarter operating margin, where lower planned trial spending should let more revenue drop to operating profit.
New Patent and FDA Review Extend the Bladder Franchise
Barrett said UroGen is "strengthening the durability of our business through the advancement of UGN-103", a next-generation bladder cancer gel designed to be faster to make and mix than Zusduri. In October, US regulators accepted the application for UGN-103 and set a decision date of June 14, 2027, while a newly issued US patent now protects both drugs into July 2044.
The drug maker also treated its first patient in an early-stage trial of UGN-501, a cancer-fighting virus for higher-risk bladder tumors. What to watch: the submission of 12-month durability data from the UGN-103 trial during the regulatory review, because matching Zusduri's response rate is needed for approval next June.
🐻 Bear Case
Rival Trials Forced a Cut to the Jelmyto Outlook
Jelmyto is UroGen's older gel for upper urinary tract tumors. Management previously held its full-year sales plan of $97 million to $101 million and called it on track, even though first-half sales had slipped from a year ago.
That plan broke in the third quarter. Jelmyto sales fell 18.2% from a year ago to $21.0 million, well below the $26.6 million to $28.6 million quarterly pace implied by the old full-year outlook, forcing UroGen to cut its 2026 forecast to about $90 million.
- Reported Q3 Jelmyto sales: $21.0 million, down 18.2% from $25.7 million a year ago
- Clean Q3 Jelmyto sales excluding a $1.5 million Medicare billing adjustment: $22.5 million, down 12.4% by our math
- Implied Q4 Jelmyto sales under the new $90 million plan: $25.3 million by our math, up 6.3% from a year ago
UroGen blamed the drop on a $1.5 million prior-year Medicare charge for discarded medicine and "ongoing competitive clinical trial enrollment activity affecting JELMTYO patient starts". Even without the one-off Medicare charge, underlying sales shrank 12.4% because rival trials are pulling patients away, and even the cut outlook requires a fourth-quarter rebound.
What to watch: fourth-quarter Jelmyto revenue against the $25.3 million implied target. Falling short again would show that rival trials and UroGen's own focus on Zusduri are permanently shrinking its original drug.
Cash Fell Another $17.4 Million Despite Operating Profit
Reporting an operating profit did not stop UroGen from burning cash. Cash and marketable securities dropped by $17.4 million in the third quarter to $90.5 million, following a $32.3 million drop in the second quarter, while total liabilities climbed to $397.1 million and shareholders' deficit widened to $125.2 million.
Interest on the $200 million Pharmakon loan and financing costs on the RTW obligation consumed $9.4 million, and UroGen paid $4.0 million for an equity stake in IntraGel Therapeutics. What to watch: fourth-quarter ending cash, because continued cash drain would push the company to draw its conditional $50 million loan tranche before June 2027.
Risks this quarter didn't answer
Four standing concerns around the commercial ramp and product pipeline got no new numbers in the third-quarter earnings release.
- Zusduri full-year sales outlook: omitted for a fourth straight quarter; an initial 2027 target in early 2027 will give the first formal benchmark.
- Time from patient enrollment form to first dose: last given as 30 to 35 days in the first quarter; any number on the call will show if clinic bottlenecks eased.
- Competition from post-surgery bladder cancer therapies: unmentioned in the release; prescriber growth in 2027 will show if rival treatments limit Zusduri.
- Reimbursement bridge from Zusduri to UGN-103: unaddressed; management still must explain how clinics bill between UGN-103 approval in 2027 and its own billing code.
👓 Other Themes
IntraGel Collaboration Adds Head and Neck Cancer Option
In August, UroGen signed a partnership with IntraGel Therapeutics to test sustained-release gel drugs outside the urinary tract. The bladder cancer specialist agreed to buy up to $7 million of IntraGel stock, investing $4 million in the third quarter, for an exclusive option to license up to three cancer treatments and a mid-stage chemotherapy gel for inoperable head and neck tumors.
💲 Other KPIs
Gross margin — the share of sales left after manufacturing costs — rose 3.5 percentage points from a year ago and edged up from 90.9% in the second quarter. High-margin Zusduri sales now make up over three-quarters of total revenue, keeping the margin above 90% while pre-approval inventory is used.
Debt and financing charges rose 17.4% from a year ago and held steady against the second quarter's $9.4 million. The bill includes $4.8 million of interest on the $200 million Pharmakon loan after borrowing an extra $75 million in February, plus $4.5 million of non-cash financing cost for the RTW royalty obligation.
Basic and diluted share count increased 5.2% from a year ago and rose 0.4% from the second quarter. Past share sales under the company's at-the-market stock offering programme and employee stock compensation drove the year-over-year increase.
🔮 Guidance
Cut. The new target lowers the middle of the prior plan by $9 million and points to a 4.3% drop from 2025 sales of $94.0 million. By our math, hitting $90 million still requires $25.3 million in the fourth quarter, up from $21.0 million this quarter and up 6.3% from a year ago, despite ongoing competition from clinical trials.
Unchanged, but pointed "toward the upper end of the range". After raising the plan by $20 million last quarter, UroGen spent $206.0 million in the first nine months, including $73.2 million in the third quarter due to the UGN-103 application fee. By our math, the $270 million top end leaves $64.0 million for the fourth quarter, down from this quarter's peak.
Unchanged. This non-cash employee stock cost sits inside the total operating expense plan. Through the first nine months of 2026, share-based compensation totaled $16.2 million ($6.2 million in the third quarter), leaving $3.8 million to $7.8 million for the fourth quarter by our math.
❓ Key Questions
How fast are patient enrollment forms turning into treatments?
UroGen reported a 30-to-35-day wait from enrollment to treatment in the first quarter and aimed for two to three weeks by year-end, but gave no number for two quarters. Knowing the current wait shows whether Q3 growth came from clearing a backlog.
Why did operating cash flow lag the $8.3M operating profit?
Cash dropped by $17.4 million even though the business earned $8.3 million in operating profit and spent only $4.0 million on IntraGel stock. Investors need to know how much cash went into inventory and unpaid customer bills as Zusduri scaled.
What drives the implied fourth-quarter rebound in Jelmyto sales?
By our math, reaching the reduced $90 million target requires $25.3 million of Jelmyto sales in the fourth quarter, up from $22.5 million excluding one-offs in the third quarter. Management has not explained why rival trial pressure would ease in the fourth quarter.
How will clinics bill for UGN-103 before it gets a J-code?
With an FDA decision on UGN-103 set for June 14, 2027, UroGen plans to move patients over from Zusduri. Without a permanent billing code at launch, clinics could face the same reimbursement delays that slowed Zusduri in 2025.